Funded Tech Companies
Asceneuron
Headquartered in Lausanne, Asceneuron has funding from SR One Capital Management, OrbiMed and Sofinnova Partners.
Company Overview
Company Name
Asceneuron
Company Status
Private & Independent
Industry
Life Sciences
Funding Rounds
Total Funding
Contact Information
Mailing Address
EPFL Innovation Park Bâtiment B
Lausanne, CH-1015
Switzerland
Lausanne, CH-1015
Switzerland
Phone
Undisclosed
Website
Email Address
Not Recorded
Company Background Information
Overview
We have one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients. Asceneuron has two small molecule O-GlcNAcase inhibitors (ASN51 and ASN90) that leverage a central protein modification system to slow protein aggregation. Both ASN51 and ASN90 have completed 3 Phase 1 studies, demonstrating high O-GlcNAcase inhibition in the brain.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
7/16/2024
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Barbara Pavik
Chief Operating Officer
Sandra Millet
VP - Bus. Development
Andrin Cerletti
VP - R & D
Ryan Schubert
VP - Regulatory Affairs
Ruhi Ahmed
Company Investors
- SR One Capital Management (Amit Shah)
- OrbiMed (Dina Chaya)
- Sofinnova Partners (Henrijette Richter)
- M Ventures
- EQT Life Sciences (Philip Scheltens)
- Novo Holdings (Naveed Siddiqi)
- Johnson & Johnson Innovation
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs